Astellas

Oncology

On the forefront of healthcare change, turning innovative sc...

Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.

News

Astellas adds to claudin clout with $1.3bn+ Evopoint deal

Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.

News

Ophthalmologists' phoropter for eye exams

FDA changes its mind on Astellas' geographic atrophy drug

Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy, getting FDA approval for extended treatment.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

News

FDA says no to Astellas' geographic atrophy drug

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US.

News

winking smiley face on paper held in front of a woman's face

Astellas pulls geographic atrophy drug filing in the EU

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator.

On the forefront of healthcare change, turning innovative sc...

Astellas adds to claudin clout with $1.3bn+ Evopoint deal

FDA changes its mind on Astellas' geographic atrophy drug

A next-generation mindset: Veeva Commercial Summit 2024

FDA says no to Astellas' geographic atrophy drug

Astellas pulls geographic atrophy drug filing in the EU

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Astellas

Editor's Picks